The Crypto That’s Making Wall Street Sweat

The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.

Click here to discover our #1 crypto for the market right now – poised for massive growth

Tia Bush Biography and Net Worth

Insider of Centessa Pharmaceuticals

Tia Bush serves as Chief Quality Officer for Centessa Pharmaceuticals. Tia is a global leader who brings nearly thirty years of biotechnology quality experience to the company.

Tia’s extensive career has been spent in quality related roles of increasing responsibility at Amgen, Inc., where she joined in 1993. Most recently, Tia was Chief Quality Officer and Senior Vice President, Global Quality/Environment, Health, Safety and Sustainability where she was responsible for developing, maintaining, and continuously improving the quality management and EHSS management systems. She led an organization of more than 1,400 quality and safety professionals.

Tia currently sits on the Board of Directors for PDA and USC Health Services. She holds a BA in Biological Sciences with a minor in Chemistry from the University of Southern California, Los Angeles, USA.

What is Tia L. Bush's net worth?: The estimated net worth of Tia L. Bush is at least $2.63 million as of May 24th, 2023. Ms. Bush owns 157,102 shares of Centessa Pharmaceuticals stock worth more than $2,629,887 as of November 21st. This net worth evaluation does not reflect any other investments that Ms. Bush may own. Learn More about Tia L. Bush's net worth.
How old is Tia L. Bush?: Ms. Bush is currently 53 years old. There are 5 older executives and no younger executives at Centessa Pharmaceuticals. The oldest executive at Centessa Pharmaceuticals is Dr. David M. Chao Ph.D., Chief Administrative Officer, who is 56 years old. Learn More on Tia L. Bush's age.
How do I contact Tia L. Bush?: The corporate mailing address for Ms. Bush and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on Tia L. Bush's contact information.
Has Tia L. Bush been buying or selling shares of Centessa Pharmaceuticals?: Tia L. Bush has not been actively trading shares of Centessa Pharmaceuticals in the last ninety days. Most recently, Tia L. Bush sold 8,000 shares of the business's stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $4.48, for a transaction totalling $35,840.00. Following the completion of the sale, the insider now directly owns 157,102 shares of the company's stock, valued at $703,816.96. Learn More on Tia L. Bush's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Aaron Kantoff (Director), and Saurabh Saha (CEO). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, insiders at the sold shares 12 times. They sold a total of 380,458 shares worth more than $5,855,386.13. The most recent insider tranaction occured on October, 25th when insider Gregory M Weinhoff sold 11,742 shares worth more than $180,591.96. Insiders at Centessa Pharmaceuticals own 11.6% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 10/25/2024.

Tia L. Bush Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/24/2023	Sell	8,000	$4.48	$35,840.00	157,102
11/16/2021	Buy	5,000	$12.46	$62,300.00

Tia L. Bush Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Today's Range

Now: $16.74

$16.46

$17.35

50 Day Range

MA: $16.03

$15.04

$18.08

2 Week Range

Now: $16.74

$5.58

$18.74

Volume

622,655 shs

Average Volume

409,281 shs

Market Capitalization

$1.90 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

The Crypto That’s Making Wall Street Sweat

From Crypto 101 Media | Ad